SG11201606514SA - Preventive or therapeutic agent for kidney disease - Google Patents
Preventive or therapeutic agent for kidney diseaseInfo
- Publication number
- SG11201606514SA SG11201606514SA SG11201606514SA SG11201606514SA SG11201606514SA SG 11201606514S A SG11201606514S A SG 11201606514SA SG 11201606514S A SG11201606514S A SG 11201606514SA SG 11201606514S A SG11201606514S A SG 11201606514SA SG 11201606514S A SG11201606514S A SG 11201606514SA
- Authority
- SG
- Singapore
- Prior art keywords
- preventive
- therapeutic agent
- kidney disease
- kidney
- disease
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014022041 | 2014-02-07 | ||
PCT/JP2015/053415 WO2015119253A1 (ja) | 2014-02-07 | 2015-02-06 | 腎疾患の予防または治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201606514SA true SG11201606514SA (en) | 2016-09-29 |
Family
ID=53778050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201606514SA SG11201606514SA (en) | 2014-02-07 | 2015-02-06 | Preventive or therapeutic agent for kidney disease |
Country Status (9)
Country | Link |
---|---|
US (2) | US10349640B2 (ja) |
EP (1) | EP3103466A4 (ja) |
JP (1) | JP6460483B2 (ja) |
KR (1) | KR101870246B1 (ja) |
CN (1) | CN106102761A (ja) |
CA (1) | CA2938944C (ja) |
IL (1) | IL247111B2 (ja) |
SG (1) | SG11201606514SA (ja) |
WO (1) | WO2015119253A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015119253A1 (ja) * | 2014-02-07 | 2015-08-13 | 宮崎 徹 | 腎疾患の予防または治療剤 |
JP6666916B2 (ja) | 2015-08-06 | 2020-03-18 | 積水メディカル株式会社 | 腎疾患の検査方法 |
CN105506079B (zh) * | 2015-12-21 | 2018-10-12 | 中山大学附属第一医院 | 防治IgA肾病的干预靶点及其检测方法 |
EP3681528A4 (en) * | 2017-09-13 | 2021-07-21 | Mayo Foundation for Medical Education and Research | IDENTIFICATION AND MONITORING OF THE APOPTOSIS INHIBITOR OF MACROPHAGES |
EP3712265B1 (en) * | 2017-11-16 | 2024-01-10 | Toru Miyazaki | Variant aim |
SG11202103250UA (en) | 2018-10-01 | 2021-04-29 | Toru Miyazaki | Therapeutic agent for neurodegenerative disease |
KR102089716B1 (ko) * | 2018-10-12 | 2020-03-16 | 이화여자대학교 산학협력단 | 대식세포 사멸 억제인자의 조절제를 포함하는 염증질환의 예방 및 치료용 조성물 |
JP7159093B2 (ja) * | 2019-03-26 | 2022-10-24 | 徹 宮崎 | 血中フリー体aim増加用組成物 |
BR112022001053A2 (pt) * | 2019-07-23 | 2022-05-17 | Nestle Sa | Métodos e composições com benefícios renais para felinos |
WO2021050089A1 (en) * | 2019-09-09 | 2021-03-18 | Washington State University | Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis |
CN117794561A (zh) * | 2021-07-30 | 2024-03-29 | 宫崎彻 | 缺血性疾病的治疗剂 |
CN113907044A (zh) * | 2021-11-09 | 2022-01-11 | 福建省连江县刘氏兔业养殖场 | 一种抗病猪品系的培育方法及其应用 |
CN114747535B (zh) * | 2022-03-29 | 2024-03-22 | 华南理工大学 | 一种急性脓毒症非人灵长类动物模型及其构建方法 |
CN115011418B (zh) * | 2022-06-10 | 2024-02-06 | 南京百斯杰生物工程有限公司 | 具有稳定蛋白酶活性的液体组合物 |
WO2024014463A1 (ja) * | 2022-07-12 | 2024-01-18 | 徹 宮崎 | 腎臓結石の治療または予防剤 |
JP7504490B2 (ja) | 2022-09-01 | 2024-06-24 | 合同会社AiMIYA | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5033276B2 (ja) * | 1997-05-05 | 2012-09-26 | ストライカー コーポレイション | 急性腎不全の治療 |
US20100331244A1 (en) * | 2009-06-01 | 2010-12-30 | The University Of Tokyo | Pharmaceutical composition, food or drink, and methods related thereto |
CN103648531A (zh) * | 2010-05-20 | 2014-03-19 | 宫崎彻 | 用于预防或治疗代谢综合症的方法 |
EP2573192A4 (en) * | 2010-05-20 | 2013-11-20 | Toru Miyazaki | METHOD AND KIT FOR DIAGNOSING DISEASE ASSOCIATED WITH AIM |
JP6143015B2 (ja) | 2012-04-27 | 2017-06-07 | 宮崎 徹 | 肝疾患の予防または治療剤 |
WO2015119253A1 (ja) * | 2014-02-07 | 2015-08-13 | 宮崎 徹 | 腎疾患の予防または治療剤 |
-
2015
- 2015-02-06 WO PCT/JP2015/053415 patent/WO2015119253A1/ja active Application Filing
- 2015-02-06 KR KR1020167024671A patent/KR101870246B1/ko active IP Right Grant
- 2015-02-06 JP JP2015561061A patent/JP6460483B2/ja active Active
- 2015-02-06 SG SG11201606514SA patent/SG11201606514SA/en unknown
- 2015-02-06 IL IL247111A patent/IL247111B2/en unknown
- 2015-02-06 US US15/116,907 patent/US10349640B2/en active Active
- 2015-02-06 EP EP15746352.2A patent/EP3103466A4/en active Pending
- 2015-02-06 CA CA2938944A patent/CA2938944C/en active Active
- 2015-02-06 CN CN201580015029.XA patent/CN106102761A/zh active Pending
-
2019
- 2019-07-11 US US16/509,161 patent/US11253571B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL247111B1 (en) | 2024-03-01 |
KR101870246B1 (ko) | 2018-06-22 |
US11253571B2 (en) | 2022-02-22 |
WO2015119253A1 (ja) | 2015-08-13 |
JPWO2015119253A1 (ja) | 2017-03-30 |
IL247111B2 (en) | 2024-07-01 |
CA2938944C (en) | 2020-01-28 |
KR20160110538A (ko) | 2016-09-21 |
EP3103466A1 (en) | 2016-12-14 |
US20190364859A1 (en) | 2019-12-05 |
CN106102761A (zh) | 2016-11-09 |
US10349640B2 (en) | 2019-07-16 |
IL247111A0 (en) | 2016-09-29 |
CA2938944A1 (en) | 2015-08-03 |
EP3103466A4 (en) | 2017-11-22 |
JP6460483B2 (ja) | 2019-01-30 |
US20170172120A1 (en) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256383A1 (zh) | 治療劑 | |
IL247111A0 (en) | causes the prevention of or treatment of kidney disease | |
IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
IL253945B (en) | kdm1a inhibitors to treat the disease | |
GB201509893D0 (en) | Therapeutic agents | |
GB201517263D0 (en) | Therapeutic agents | |
GB201410816D0 (en) | Therapeutic agents | |
GB201415569D0 (en) | Therapeutic Compounds | |
HK1256356A1 (zh) | 用於誘導組織形成的化合物及其用途 | |
GB201410817D0 (en) | Therapeutic agents | |
GB201410815D0 (en) | Therapeutic agents | |
GB201509885D0 (en) | Therapeutic agents | |
HK1256358A1 (zh) | 用於誘導組織形成的化合物及其用途 | |
GB201509888D0 (en) | Therapeutic agents | |
GB201416273D0 (en) | Therapeutic compounds | |
GB201513299D0 (en) | Therapeutic agents | |
GB201521767D0 (en) | Therapeutic agents | |
SG11201700059WA (en) | Therapeutic agent for keratoconjunctive disorder | |
GB201517264D0 (en) | Therapeutic agents | |
IL286670B (en) | Compounds for inducing tissue formation and their uses | |
HK1256243A1 (zh) | 誘導組織形成的化合物及其應用 | |
GB201911521D0 (en) | Therapeutic agent | |
GB201516109D0 (en) | Therapeutic agent | |
GB201521755D0 (en) | Therapeutic agents | |
GB201521683D0 (en) | Therapeutic agents |